Frank Pajonk

Websites:

Pajonk Lab

Research Interests:

breast cancer, glioblastoma, radiation, cancer cell plasticity, stem cells, gbm, drug development, cancer stem cells,

Publications:

He L, Ioannidis A, Hoffman CJ, Arambula E, Joshi P, Whitelegge J, Liau LM, Kornblum HI, Pajonk F. Activation of the Mevalonate Pathway in Response to Anti-cancer Treatments Drives Glioblastoma Recurrences Through Activation of Rac-1. Cancer Res Commun. 2024 Jun 25; 4(6):1566-1580. view on PubMed

He L, Azizad D, Bhat K, Ioannidis A, Hoffmann CJ, Arambula E, Bhaduri A, Kornblum HI, Pajonk F. Radiation-Induced Cellular Plasticity: A Strategy for Combatting Glioblastoma. bioRxiv. 2024 May 16. view on PubMed

Ludwig K, Le Belle JE, Muthukrishnan SD, Sperry J, Condro M, Vlashi E, Pajonk F, Kornblum HI. Nicotinamide Adenine Dinucleotide Phosphate Oxidase Promotes Glioblastoma Radiation Resistance in a Phosphate and Tensin Homolog-Dependent Manner. Antioxid Redox Signal. 2023 11; 39(13-15):890-903. view on PubMed

He L, Ioannidis A, Arambula E, Hoffman CJ, Joshi P, Kathiravan A, Whitelegge J, Liau LM, Kornblum HI, Pajonk F. Activation of the mevalonate pathway in response to anti-cancer treatments drives glioblastoma recurrences through activation of Rac-1. bioRxiv. 2023 Jul 25. view on PubMed

He L, Bhat K, Ioannidis A, Pajonk F. Effects of Dopamine Receptor Antagonists and Radiation on Mouse Neural Stem/Progenitor Cells. bioRxiv. 2023 Jan 20. view on PubMed

Muthukrishnan SD, Kawaguchi R, Nair P, Prasad R, Qin Y, Johnson M, Wang Q, VanderVeer-Harris N, Pham A, Alvarado AG, Condro MC, Gao F, Gau R, Castro MG, Lowenstein PR, Deb A, Hinman JD, Pajonk F, Burns TC, Goldman SA, Geschwind DH, Kornblum HI. P300 promotes tumor recurrence by regulating radiation-induced conversion of glioma stem cells to vascular-like cells. Nat Commun. 2022 10 19; 13(1):6202. view on PubMed

Bhat K, Saki M, Cheng F, He L, Zhang L, Ioannidis A, Nathanson D, Tsang J, Bensinger SJ, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. J Natl Cancer Inst. 2021 08 02; 113(8):1094-1104. view on PubMed

He L, Bhat K, Ioannidis A, Zhang L, Nguyen NT, Allen JE, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma. Radiother Oncol. 2021 08; 161:140-147. view on PubMed

Muftuoglu Y, Pajonk F. Targeting Glioma Stem Cells. Neurosurg Clin N Am. 2021 Apr; 32(2):283-289. view on PubMed

He L, Bhat K, Duhacheck-Muggy S, Ioannidis A, Zhang L, Nguyen NT, Moatamed NA, Pajonk F. Tumor necrosis factor receptor signaling modulates carcinogenesis in a mouse model of breast cancer. Neoplasia. 2021 02; 23(2):197-209. view on PubMed

Bhat K, Medina P, He L, Zhang L, Saki M, Ioannidis A, Nguyen NT, Sodhi SS, Sung D, Magyar CE, Liau LM, Kornblum HI, Pajonk F. 1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine treatment after brain irradiation preserves cognitive function in mice. Neuro Oncol. 2020 10 14; 22(10):1484-1494. view on PubMed

Bhat K, Saki M, Vlashi E, Cheng F, Duhachek-Muggy S, Alli C, Yu G, Medina P, He L, Damoiseaux R, Pellegrini M, Zemke NR, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. Proc Natl Acad Sci U S A. 2020 05 19; 117(20):11085-11096. view on PubMed

Saki M, Bhat K, Sodhi SS, Nguyen NT, Kornblum HI, Pajonk F. Effects of Brain Irradiation in Immune-Competent and Immune-Compromised Mouse Models. Radiat Res. 2020 02; 193(2):186-194. view on PubMed

Duhachek-Muggy S, Bhat K, Medina P, Cheng F, He L, Alli C, Saki M, Muthukrishnan SD, Ruffenach G, Eghbali M, Vlashi E, Pajonk F. Radiation mitigation of the intestinal acute radiation injury in mice by 1-[(4-nitrophenyl)sulfonyl]-4-phenylpiperazine. Stem Cells Transl Med. 2020 01; 9(1):106-119. view on PubMed

Zhang L, Bailleul J, Yazal T, Dong K, Sung D, Dao A, Gosa L, Nathanson D, Bhat K, Duhachek-Muggy S, Alli C, Dratver MB, Pajonk F, Vlashi E. PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation. Breast Cancer Res Treat. 2019 Nov; 178(1):75-86. view on PubMed

Steinberg ML, McBride WH, Vlashi E, Pajonk F. If It Seems Too Good to Be True…. Int J Radiat Oncol Biol Phys. 2019 02 01; 103(2):305-307. view on PubMed

Bhat K, Sandler K, Duhachek-Muggy S, Alli C, Cheng F, Moatamed NA, Magyar CE, Du L, Li G, McCloskey S, Vlashi E, Pajonk F. Serum erythropoietin levels, breast cancer and breast cancer-initiating cells. Breast Cancer Res. 2019 01 30; 21(1):17. view on PubMed

Bhat K, Duhachek-Muggy S, Ramanathan R, Saki M, Alli C, Medina P, Damoiseaux R, Whitelegge J, McBride WH, Schaue D, Vlashi E, Pajonk F. 1-(4-nitrobenzenesulfonyl)-4-penylpiperazine increases the number of Peyer's patch-associated regenerating crypts in the small intestines after radiation injury. Radiother Oncol. 2019 03; 132:8-15. view on PubMed

Zhang L, Bochkur Dratver M, Yazal T, Dong K, Nguyen A, Yu G, Dao A, Bochkur Dratver M, Duhachek-Muggy S, Bhat K, Alli C, Pajonk F, Vlashi E. Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):195-207. view on PubMed

Garrett M, Sperry J, Braas D, Yan W, Le TM, Mottahedeh J, Ludwig K, Eskin A, Qin Y, Levy R, Breunig JJ, Pajonk F, Graeber TG, Radu CG, Christofk H, Prins RM, Lai A, Liau LM, Coppola G, Kornblum HI. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer Metab. 2018; 6:4. view on PubMed

Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, Ma L, Marples B, Pajonk F, Park CC, Schaue D, Tran PT, Bernhard EJ. The Future of Radiobiology. J Natl Cancer Inst. 2018 04 01; 110(4):329-340. view on PubMed

Qi XS, Pajonk F, McCloskey S, Low DA, Kupelian P, Steinberg M, Sheng K. Radioresistance of the breast tumor is highly correlated to its level of cancer stem cell and its clinical implication for breast irradiation. Radiother Oncol. 2017 09; 124(3):455-461. view on PubMed

Duhachek-Muggy S, Bhat K, Vlashi E, Pajonk F. Growth Differentiation Factor 11 does not Mitigate the Lethal Effects of Total-Abdominal Irradiation. Radiat Res. 2017 11; 188(5):469-475. view on PubMed

Vlashi E, Chen AM, Boyrie S, Yu G, Nguyen A, Brower PA, Hess CB, Pajonk F. Radiation-Induced Dedifferentiation of Head and Neck Cancer Cells Into Cancer Stem Cells Depends on Human Papillomavirus Status. Int J Radiat Oncol Biol Phys. 2016 Apr 01; 94(5):1198-206. view on PubMed

Yu VY, Nguyen D, Pajonk F, Kupelian P, Kaprealian T, Selch M, Low DA, Sheng K. Incorporating cancer stem cells in radiation therapy treatment response modeling and the implication in glioblastoma multiforme treatment resistance. Int J Radiat Oncol Biol Phys. 2015 Mar 15; 91(4):866-75. view on PubMed

Vlashi E, Pajonk F. The metabolic state of cancer stem cells-a valid target for cancer therapy? Free Radic Biol Med. 2015 Feb; 79:264-8. view on PubMed

Vlashi E, Pajonk F. Cancer stem cells, cancer cell plasticity and radiation therapy. Semin Cancer Biol. 2015 Apr; 31:28-35. view on PubMed

Vlashi E, Lagadec C, Vergnes L, Reue K, Frohnen P, Chan M, Alhiyari Y, Dratver MB, Pajonk F. Metabolic differences in breast cancer stem cells and differentiated progeny. Breast Cancer Res Treat. 2014 Aug; 146(3):525-34. view on PubMed

Lagadec C, Vlashi E, Bhuta S, Lai C, Mischel P, Werner M, Henke M, Pajonk F. Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients. BMC Cancer. 2014 Mar 05; 14:152. view on PubMed

Lagadec C, Vlashi E, Frohnen P, Alhiyari Y, Chan M, Pajonk F. The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells. Stem Cells. 2014 Jan; 32(1):135-44. view on PubMed

Pajonk F, Vlashi E. Characterization of the stem cell niche and its importance in radiobiological response. Semin Radiat Oncol. 2013 Oct; 23(4):237-41. view on PubMed

Vlashi E, Lagadec C, Chan M, Frohnen P, McDonald AJ, Pajonk F. Targeted elimination of breast cancer cells with low proteasome activity is sufficient for tumor regression. Breast Cancer Res Treat. 2013 Sep; 141(2):197-203. view on PubMed

Lagadec C, Vlashi E, Alhiyari Y, Phillips TM, Bochkur Dratver M, Pajonk F. Radiation-induced Notch signaling in breast cancer stem cells. Int J Radiat Oncol Biol Phys. 2013 Nov 01; 87(3):609-18. view on PubMed

Steinberg M, McBride WH, Vlashi E, Pajonk F. National Institutes of Health funding in radiation oncology: a snapshot. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):234-40. view on PubMed

Falkai P, Malchow B, Wobrock T, Gruber O, Schmitt A, Honer WG, Pajonk FG, Sun F, Cannon TD. The effect of aerobic exercise on cortical architecture in patients with chronic schizophrenia: a randomized controlled MRI study. Eur Arch Psychiatry Clin Neurosci. 2013 Sep; 263(6):469-73. view on PubMed

Lagadec C, Pajonk F. Catch-22: does breast cancer radiotherapy have negative impacts too? Future Oncol. 2012 Jun; 8(6):643-5. view on PubMed

Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. Radiation-induced reprogramming of breast cancer cells. Stem Cells. 2012 May; 30(5):833-44. view on PubMed

Lagadec C, Dekmezian C, Bauché L, Pajonk F. Oxygen levels do not determine radiation survival of breast cancer stem cells. PLoS One. 2012; 7(3):e34545. view on PubMed

Della Donna L, Lagadec C, Pajonk F. Radioresistance of prostate cancer cells with low proteasome activity. Prostate. 2012 Jun 01; 72(8):868-74. view on PubMed

Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, Reue K, Christofk H, Mischel PS, Pajonk F. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A. 2011 Sep 20; 108(38):16062-7. view on PubMed

Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar; 11(3):254-84. view on PubMed

Evers P, Lee PP, DeMarco J, Agazaryan N, Sayre JW, Selch M, Pajonk F. Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma. BMC Cancer. 2010 Jul 21; 10:384. view on PubMed

Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells. 2010 Apr; 28(4):639-48. view on PubMed

Lagadec C, Vlashi E, Della Donna L, Meng Y, Dekmezian C, Kim K, Pajonk F. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res. 2010; 12(1):R13. view on PubMed

Vlashi E, Pajonk F. Targeted cancer stem cell therapies start with proper identification of the target. Mol Cancer Res. 2010 Feb; 8(2):291; author reply 291. view on PubMed

Vlashi E, Mattes M, Lagadec C, Donna LD, Phillips TM, Nikolay P, McBride WH, Pajonk F. Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells. Transl Oncol. 2010 Feb; 3(1):50-5. view on PubMed

Vlashi E, McBride WH, Pajonk F. Radiation responses of cancer stem cells. J Cell Biochem. 2009 Oct 01; 108(2):339-42. view on PubMed

Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y. Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. Int J Radiat Oncol Biol Phys. 2009 Aug 01; 74(5):1580-91. view on PubMed

Vlashi E, Kim K, Lagadec C, Donna LD, McDonald JT, Eghbali M, Sayre JW, Stefani E, McBride W, Pajonk F. In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst. 2009 Mar 04; 101(5):350-9. view on PubMed

Phillips TM, Kim K, Vlashi E, McBride WH, Pajonk F. Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia. 2007 Dec; 9(12):1122-9. view on PubMed

Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006 Dec 20; 98(24):1777-85. view on PubMed

Pajonk F, Riedisser A, Henke M, McBride WH, Fiebich B. The effects of tea extracts on proinflammatory signaling. BMC Med. 2006 Dec 01; 4:28. view on PubMed

Pajonk F, Grumann T, McBride WH. The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation. Neoplasia. 2006 Dec; 8(12):1037-41. view on PubMed

Henke M, Mattern D, Pepe M, Bézay C, Weissenberger C, Werner M, Pajonk F. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol. 2006 Oct 10; 24(29):4708-13. view on PubMed

van Ophoven A, Rossbach G, Pajonk F, Hertle L. Safety and efficacy of hyperbaric oxygen therapy for the treatment of interstitial cystitis: a randomized, sham controlled, double-blind trial. J Urol. 2006 Oct; 176(4 Pt 1):1442-6. view on PubMed

Fekete MR, McBride WH, Pajonk F. Anthracyclines, proteasome activity and multi-drug-resistance. BMC Cancer. 2005 Sep 13; 5:114. view on PubMed

Pajonk F, van Ophoven A, Weissenberger C, McBride WH. The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism. BMC Cancer. 2005 Jul 07; 5:76. view on PubMed

Pajonk F, van Ophoven A, McBride WH. Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res. 2005 Jun 01; 65(11):4836-43. view on PubMed

Kessler H, Pajonk FG, Supprian T, Falkai P, Multhaup G, Bayer TA. [The role of copper in the pathophysiology of Alzheimer's disease]. Nervenarzt. 2005 May; 76(5):581-5. view on PubMed

Pajonk FG, Wobrock T, Falkai P. [Longterm therapy of schizophrenia]. Fortschr Neurol Psychiatr. 2005 Apr; 73(4):218-31; quiz 232-4. view on PubMed

Pajonk FG, Ruchholtz S, Waydhas C, Schneider-Axmann T. Long-term follow-up after severe suicide attempt by multiple blunt trauma. Eur Psychiatry. 2005 Mar; 20(2):115-20. view on PubMed

Pajonk FG, Wobrock T, Falkai P. [Longterm therapy of schizophrenia]. Fortschr Neurol Psychiatr. 2005 Mar; 73(3):161-74; quiz 175-7. view on PubMed

Pajonk F, Scholber J, Fiebich B. Hypericin-an inhibitor of proteasome function. Cancer Chemother Pharmacol. 2005 May; 55(5):439-46. view on PubMed

Wobrock T, Falkai P, Pajonk FG. [Acute treatment of schizophrenia]. Fortschr Neurol Psychiatr. 2004 Dec; 72(12):705-23; quiz 724-6. view on PubMed

Pajonk F, Weil A, Sommer A, Suwinski R, Henke M. The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene. 2004 Nov 25; 23(55):8987-91. view on PubMed

Retz W, Retz-Junginger P, Hengesch G, Schneider M, Thome J, Pajonk FG, Salahi-Disfan A, Rees O, Wender PH, Rösler M. Psychometric and psychopathological characterization of young male prison inmates with and without attention deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2004 Aug; 254(4):201-8. view on PubMed

Pajonk FG, Lubda J, Sittinger H, Moecke H, Andresen B, Von Knobelsdorff G. [Assessment of psychiatric emergencies by physicians in the pre-hospital emergency medical system. A re-evaluation after 7 years]. Anaesthesist. 2004 Aug; 53(8):709-16. view on PubMed

McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, Dougherty GJ, Iwamoto KS, Pervan M, Liao YP. A sense of danger from radiation. Radiat Res. 2004 Jul; 162(1):1-19. view on PubMed

Köllner V, Lautenschläger KA, Pajonk FG. [Psychooncology. New aspects for urology]. Urologe A. 2004 Mar; 43(3):296-301. view on PubMed

Wobrock T, Pajonk FG, Falkai P. [Schizophrenia]. Fortschr Neurol Psychiatr. 2004 Mar; 72(3):164-74. view on PubMed

Wobrock T, Pajonk FG, Falkai P. [Schizophrenia]. Fortschr Neurol Psychiatr. 2004 Feb; 72(2):98-113. view on PubMed

Pajonk FG. Risperidone in acute and long-term therapy of schizophrenia--a clinical profile. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan; 28(1):15-23. view on PubMed

McBride WH, Iwamoto KS, Syljuasen R, Pervan M, Pajonk F. The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene. 2003 Sep 01; 22(37):5755-73. view on PubMed

Pajonk FG, Fleiter B. [Psychopharmacological treatment in the pre-clinical emergency medicine]. Anaesthesist. 2003 Jul; 52(7):577-85. view on PubMed

Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care. 2003 May; 26(5):1597-605. view on PubMed

Pajonk FG, Schreiner A, Peters S, Rettig K, Degner D, Rüther E. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis]. Fortschr Neurol Psychiatr. 2003 May; 71(5):249-54. view on PubMed

Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res. 2002 Sep 15; 62(18):5230-5. view on PubMed

Pajonk F, McBride WH. Survival of AIDS patients with primary central nervous system lymphoma may be improved by the radiosensitizing effects of highly active antiretroviral therapy. AIDS. 2002 May 24; 16(8):1195-6. view on PubMed

Pajonk FG, Fischer A, Waydhas C, Bregenzer T, Schweiberer L. [Outcome of long-term intensive therapy of surgery patients]. Unfallchirurg. 2002 May; 105(5):423-30. view on PubMed

Pajonk FG, Holzbach R, Naber D. Comparing the efficacy of atypical antipsychotics in open uncontrolled versus double-blind controlled trials in schizophrenia. Psychopharmacology (Berl). 2002 Jun; 162(1):29-36. view on PubMed

Pajonk F, Riess K, Sommer A, McBride WH. N-acetyl-L-cysteine inhibits 26S proteasome function: implications for effects on NF-kappaB activation. Free Radic Biol Med. 2002 Mar 15; 32(6):536-43. view on PubMed

Pajonk F, Weissenberger C, Witucki G, Henke M. Vitiligo at the sites of irradiation in a patient with Hodgkin's disease. Strahlenther Onkol. 2002 Mar; 178(3):159-62. view on PubMed

McBride WH, Pajonk F, Chiang CS, Sun JR. NF-kappa B, cytokines, proteasomes, and low-dose radiation exposure. Mil Med. 2002 Feb; 167(2 Suppl):66-7. view on PubMed

Pajonk F, McBride WH. The proteasome in cancer biology and treatment. Radiat Res. 2001 Nov; 156(5 Pt 1):447-59. view on PubMed

Pajonk F, Schlessmann S, Guttenberger R, Henke M. Epithelial cells in the peripheral blood of patients with cancer of the head and neck: incidence, detection and possible clinical significance. Radiother Oncol. 2001 May; 59(2):213-7. view on PubMed

Pajonk F, McBride WH. Ionizing radiation affects 26s proteasome function and associated molecular responses, even at low doses. Radiother Oncol. 2001 May; 59(2):203-12. view on PubMed

Pajonk F, McBride WH. Comment on double-strand break repair and rapamycin treatment. Int J Radiat Biol. 2000 Dec; 76(12):1691-3. view on PubMed

Pajonk F, Pajonk K, McBride WH. Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys. 2000 Jul 01; 47(4):1025-32. view on PubMed

Pajonk F, Pajonk K, McBride WH. Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst. 1999 Nov 17; 91(22):1956-60. view on PubMed

Henke M, Guttenberger R, Barke A, Pajonk F, Pötter R, Frommhold H. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol. 1999 Feb; 50(2):185-90. view on PubMed

Pajonk F, Flick H, Mittelviefhaus H, Slanina J. Postoperative pterygium prevention by radiotherapy with strontium-90 beta-rays. Front Radiat Ther Oncol. 1997; 30:259-64. view on PubMed